miR‑576‑5p promotes epithelial‑to‑mesenchymal transition in colorectal cancer by targeting the Wnt5a‑mediated Wnt/β‑catenin signaling pathway

Luo,Jialin; Liu,Luying; Shen,Jinwen; Zhou,Ning; Feng,Yanru; Zhang,Na; Sun,Quanquan; Zhu,Yuan

doi:10.3892/mmr.2020.11733

miR‑576‑5p promotes epithelial‑to‑mesenchymal transition in colorectal cancer by targeting the Wnt5a‑mediated Wnt/β‑catenin signaling pathway

Authors:
- Jialin Luo
- Luying Liu
- Jinwen Shen
- Ning Zhou
- Yanru Feng
- Na Zhang
- Quanquan Sun
- Yuan Zhu
View Affiliations

Affiliations: Institute of Cancer and Basic Medicine of Chinese Academy of Sciences; Department of Radiation Oncology, Cancer Hospital of The University of Chinese Academy of Sciences; Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: November 25, 2020 https://doi.org/10.3892/mmr.2020.11733
Article Number: 94
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of the most common types of malignancy and the third most commonly diagnosed form of cancer worldwide, ranking as the fourth leading cause of cancer‑associated mortality. MicroRNA (miR)‑576‑5p has been reported to be highly expressed in patients with CRC; however, its biological role remains unclear. The present study aimed therefore to investigate the biological role and underlying mechanism of miR‑576‑5p in CRC cell line SW480. The viability of SW480 cells following transfection with miR‑576‑5p mimic or inhibitor was analyzed using MTT assay. Wound healing and Transwell assays were performed to determine the cell migratory and invasive abilities, respectively. A dual luciferase reporter assay was used to verify the predicted binding site between miR‑576‑5p and Wnt5a. Reverse transcription‑quantitative PCR and western blotting were used to analyze the expression levels of miR‑576‑5p, E‑cadherin, N‑cadherin, vimentin, Snail1, Wnt5a, β‑catenin, c‑myc, cyclin D1 and p/t‑c‑Jun. Using bioinformatics analysis, high expression of miR‑576‑5p was found not only in tumor tissues, compared with the normal tissue, but also in CRC cells, compared with NCM460 cells. Furthermore, the inhibition of miR‑576‑5p expression significantly decreased the cell viability and the migratory and invasive abilities of SW480 cells, and suppressed the epithelial‑to‑mesenchymal transition (EMT). In addition, miR‑576‑5p could interact with Wnt5a and regulate the expression level of Wnt5a in order to influence the activity of Wnt/β‑catenin signaling. The results from rescue experiments further demonstrated that the effect of miR‑576‑5p overexpression on cell metastasis and EMT was reversed by Wnt5a overexpression or treatment with XAV‑939, which is an inhibitor of the Wnt/β‑catenin signaling pathway. In conclusion, the findings from the present study suggested that inhibition of miR‑576‑5p may suppress SW480 cell metastasis and EMT by targeting Wnt5a and regulating the Wnt5a‑mediated Wnt/β‑catenin signaling pathway, providing a potential therapeutic target for the treatment of CRC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Lu CW, ZhouDDXieTHaoJ L, Pant OP, Lu CB and Liu XF: HOXAll antisense long noncoding RNA (HOXAll-AS): A promising lncRNA in human cancers. Cancer Med. 7:3792–3799. 2018. View Article : Google Scholar : PubMed/NCBI
3	McArdle CS and Hole DJ: Outcome following surgery for colorectal cancer: Analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer. 86:331–335. 2002. View Article : Google Scholar : PubMed/NCBI
4	Holm M, Saraswat M, Joenväärä S, Ristimäki A, Haglund C and Renkonen R: Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. PLoS One. 13:e01953542018. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Tsuchiya S, Okuno Y and Tsujimoto G: MicroRNA: Biogenetic and functional mechanisms and involvements in cell differentiation and cancer. J Pharmacol Sci. 101:267–270. 2006. View Article : Google Scholar : PubMed/NCBI
7	Bartels CL and Tsongalis GJ: MicroRNAs: Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009. View Article : Google Scholar : PubMed/NCBI
8	Sun GL, Li Z, Wang WZ, Chen Z, Zhang L, Li Q, Wei S, Li BW, Xu JH, Chen L, et al: miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt/beta-catenin signaling pathway. J Gastroenterol. 53:725–739. 2018. View Article : Google Scholar : PubMed/NCBI
9	Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L, Han B, Meng J, Yan Z, Yan X and Jiao S: MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget. 6:25266–25280. 2015. View Article : Google Scholar : PubMed/NCBI
10	Jiang C, Hu X, Alattar M and Zhao H: miRNA expression profiles associated with diagnosis and prognosis in lung cancer. Expert Rev Anticancer Ther. 14:453–461. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kordass T, Weber CEM, Eisel D, Pane AA, Osen W and Eichmüller SB: miR-193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion in vitro. Oncotarget. 9:32507–32522. 2018. View Article : Google Scholar : PubMed/NCBI
12	Ni XF, Zhao LH, Li G, Hou M, Su M, Zou CL and Deng X: MicroRNA-548-3p and MicroRNA-576-5p enhance the migration and invasion of esophageal squamous cell carcinoma cells via NRIP1 down-regulation. Neoplasma. 65:881–887. 2018. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Chen J, Wang L, Chen L, Du Z, Zhu L, Cui M, Zhang M and Song L: Linc-PINT acted as a tumor suppressor by sponging miR-543 and miR-576-5p in esophageal cancer. J Cell Biochem. 120:19345–19357. 2019. View Article : Google Scholar : PubMed/NCBI
14	Wang YN, Chen ZH and Chen WC: Novel circulating microRNAs expression profile in colon cancer: A pilot study. Eur J Med Res. 22:512017. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Ghahhari NM and Babashah S: Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 51:1638–1649. 2015. View Article : Google Scholar : PubMed/NCBI
17	Kumawat K and Gosens R: WNT-5A: Signaling and functions in health and disease. Cell Mol Life Sci. 73:567–587. 2016. View Article : Google Scholar : PubMed/NCBI
18	Calin GA and Croce CM: MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 66:7390–7394. 2006. View Article : Google Scholar : PubMed/NCBI
19	Zhu W, Luo X, Fu H, Liu L, Sun P and Wang Z: MiR-3653 inhibits the metastasis and epithelial-mesenchymal transition of colon cancer by targeting Zeb2. Pathol Res Pract. 215:1525772019. View Article : Google Scholar : PubMed/NCBI
20	Chen E, Li Q, Wang H, Yang F, Min L and Yang J: MiR-92a promotes tumorigenesis of colorectal cancer, a transcriptomic and functional based study. Biomed Pharmacother. 106:1370–1377. 2018. View Article : Google Scholar : PubMed/NCBI
21	Huang L, Zhang Y, Li Z, Zhao X, Xi Z, Chen H, Shi H, Xin T, Shen R and Wang T: MiR-4319 suppresses colorectal cancer progression by targeting ABTB1. United European Gastroenterol J. 7:517–528. 2019. View Article : Google Scholar : PubMed/NCBI
22	Rodrigo JP, Martínez P, Allonca E, Alonso-Durán L, Suárez C, Astudillo A and García-Pedrero J: Immunohistochemical markers of distant metastasis in laryngeal and hypopharyngeal squamous cell carcinomas. Clin Exp Metastasis. 31:317–325. 2014. View Article : Google Scholar : PubMed/NCBI
23	Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
24	Li D, Tian B and Jin X: miR-630 inhibits epithelial-to-mesenchymal transition (EMT) by regulating the Wnt/β-catenin pathway in gastric cancer cells. Oncol Res. 27:9–17. 2018. View Article : Google Scholar : PubMed/NCBI
25	Montorsi L, Guizzetti F, Alecci C, Caporali A, Martello A, Atene CG, Parenti S, Pizzini S, Zanovello P, Bortoluzzi S, et al: Loss of ZFP36 expression in colorectal cancer correlates to wnt/β-catenin activity and enhances epithelial-to-mesenchymal transition through upregulation of ZEB1, SOX9 and MACC1. Oncotarget. 7:59144–59157. 2016. View Article : Google Scholar : PubMed/NCBI
26	Kikuchi A, Yamamoto H, Sato A and Matsumoto S: Wnt5a: Its signalling, functions and implication in diseases. Acta Physiol (Oxf). 204:17–33. 2012. View Article : Google Scholar : PubMed/NCBI
27	Asem MS, Buechler S, Wates RB, Miller DL and Stack MS: Wnt5a Signaling in Cancer. Cancers (Basel). 8:792016. View Article : Google Scholar
28	Qin L, Yin YT, Zheng FJ, Peng LX, Yang CF, Bao YN, Liang YY, Li XJ, Xiang YQ, Sun R, et al: WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis. Oncotarget. 6:10239–10252. 2015. View Article : Google Scholar : PubMed/NCBI
29	Da Forno PD, Pringle JH, Hutchinson P, Osborn J, Huang Q, Potter L, Hancox RA, Fletcher A and Saldanha GS: WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res. 14:5825–5832. 2008. View Article : Google Scholar : PubMed/NCBI
30	Wang T, Liu X and Wang J: Up-regulation of Wnt5a inhibits proliferation and migration of hepatocellular carcinoma cells. J Cancer Res Ther. 15:904–908. 2019. View Article : Google Scholar : PubMed/NCBI
31	Bi L, Liu X, Wang C, Cao Y, Mao R, Li P and Geng M: Wnt5a involved in regulation of the biological behavior of hepatocellular carcinoma. Int J Clin Exp Pathol. 7:987–995. 2014.PubMed/NCBI
32	Prasad CP, Manchanda M, Mohapatra P and Andersson T: WNT5A as a therapeutic target in breast cancer. Cancer Metastasis Rev. 37:767–778. 2018. View Article : Google Scholar : PubMed/NCBI
33	Li Q and Chen H: Silencing of Wnt5a during colon cancer metastasis involves histone modifications. Epigenetics. 7:551–558. 2012. View Article : Google Scholar : PubMed/NCBI
34	Cheng R, Sun B, Liu Z, Zhao X, Qi L, Li Y and Gu Q: Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition. J Cell Physiol. 229:1908–1917. 2014. View Article : Google Scholar : PubMed/NCBI
35	van Amerongen R, Mikels A and Nusse R: Alternative wnt signaling is initiated by distinct receptors. Sci Signal. 1:re92008. View Article : Google Scholar : PubMed/NCBI
36	Howard S, Deroo T, Fujita Y and Itasaki N: A positive role of cadherin in Wnt/β-catenin signalling during epithelial-mesenchymal transition. PLoS One. 6:e238992011. View Article : Google Scholar : PubMed/NCBI
37	Wijnhoven BP, Dinjens WN and Pignatelli M: E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg. 87:992–1005. 2000. View Article : Google Scholar : PubMed/NCBI
38	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
39	Shi L, Wu YX, Yu JH, Chen X, Luo XJ and Yin YR: Research of the relationship between β-catenin and c-myc-mediated Wnt pathway and laterally spreading tumors occurrence. Eur Rev Med Pharmacol Sci. 21:252–257. 2017.PubMed/NCBI
40	Valenta T, Hausmann G and Basler K: The many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012. View Article : Google Scholar : PubMed/NCBI
41	Fang Y, Shen ZY, Zhan YZ, Feng XC, Chen KL, Li YS, Deng HJ, Pan SM, Wu DH and Ding Y: CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis. Nat Commun. 10:39812019. View Article : Google Scholar : PubMed/NCBI
42	Xie C, Pan Y, Hao F, Gao Y, Liu Z, Zhang X, Xie L, Jiang G, Li Q and Wang E: C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells. APMIS. 122:1251–1258. 2014. View Article : Google Scholar : PubMed/NCBI